title: Prognostic value of pre-operative serum CA 15.3 levels in breast cancer.
abstract: BACKGROUND
  CA15.3 (also known as MUCI) is the most widely used marker in breast cancer. The aim of the present work was the evaluation of the prognostic value of preoperative serum CA15.3 levels in patients with primary breast cancer.
  
  
  METHODS
  This study included 818 women with a histologically verified diagnosis of invasive breast cancer. The serum values of CA15.3 were investigated at the time of primary diagnosis by means of an immunoradiometric assay based on the "sandwich" principle. The median follow-up period of patients free of recurrence was 38 months.
  
  
  RESULTS
  Pre-operative CA15.3 serum levels ranged from 6 to 452 U/ml. Elevated CA15.3 levels (>30 U/ml) were found in 15.2% of patients. Statistical analysis showed that pre-operative CA15.3 serum levels were significantly higher in patients with large size tumors (T3 or T4) (p = 0.0001), as well as in those with node-positive tumors (p = 0.0001). In the univariate analysis, high CA15.3 levels were significantly associated with a lower probability of both relapse-free and overall survival in the overall group of patients (p = 0.0001 and p = 0.004, respectively) and in the subgroup with node-positive breast cancer (p = 0.001 and p = 0.03, respectively). In addition, multivariate analysis demonstrated that pre-operative levels of the antigen were significantly and independently associated with relapse-free survival in the overall group of patients, as well as in the subgroup of patients with node-positive breast cancer (p = 0.02 and p = 0.01, respectively).
  
  
  CONCLUSIONS
  These results show that high pre-operative CA15.3 levels correlate with large size tumors and the presence of lymph node metastases and suggest that this antigen could be used as an additional prognostic marker.
authors.affiliation: Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.
authors.forename: Arancha
authors.initials: A
authors.lastname: Martín
authors.forename: Ma Daniela
authors.initials: MD
authors.lastname: Corte
authors.forename: Ana Ma
authors.initials: AM
authors.lastname: Alvarez
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Rodriguez
authors.forename: Alejandro
authors.initials: A
authors.lastname: Andicoechea
authors.forename: Miguel
authors.initials: M
authors.lastname: Bongera
authors.forename: Sara
authors.initials: S
authors.lastname: Junquera
authors.forename: Diego
authors.initials: D
authors.lastname: Pidal
authors.forename: Teresa
authors.initials: T
authors.lastname: Allende
authors.forename: José L García
authors.initials: JL
authors.lastname: Muñiz
authors.forename: Francisco
authors.initials: F
authors.lastname: Vizoso
mesh_terms: D001943:Breast Neoplasms / Q000097:blood*; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood*; D011379:Prognosis; D012008:Recurrence
chemical_list: D018396:Mucin-1